Kaplan-Meier landmark analyses (landmark populations). (A) PFS according to molecular response at 3 months. For BCR-ABL ≤1% vs >1% to 10%, P = .003; for >1% to 10% vs >10%, P < .0001. Of note, 212 (90%) of the 235 patients with BCR-ABL >10% at 3 months in this analysis had CHR. (B) OS according to molecular response at 3 months. For BCR-ABL ≤1% vs >1% to 10%, P = .285; for >1% to 10% vs >10%, P < .0001. (C) PFS according to molecular response at 6 months. For BCR-ABL ≤1% vs >1% to 10%, P = .001; for >1% to 10% vs >10%, P = .017. (D) OS according to molecular response at 6 months. For BCR-ABL ≤1% vs >1% to 10%, P = .554; for >1% to 10% vs >10%, P = .001. Patients without a molecular assessment at 3 or 6 months were not included in the corresponding analyses. In addition, patients who progressed (for PFS) or died (for OS) before the landmark time point were excluded from those analyses.